Merck & Co’s V114 is a 15-valent pneumococcal capsular polysaccharide conjugate vaccine, which is currently in Phase III development in the US and EU.
VB-111 (VBL Therapeutics) will be able to succeed in the US as an add-on therapy to Avastin
(bevacizumab; Genentech/Roche/Chugai) in the second-line of therapy, should it present positive data
from the Phase III GLOBE study.
Afinitor (everolimus; Novartis) is an orally available analog of the mammalian target of rapamycin (mTOR), which mediates the signal transduction pathways required for cell cycle progression from G1 to S phase.
Pfizer’s RSV preF vaccine is based on the prefusion form of the RSV fusion protein, aided by the discovery of the crystal structure of key viral proteins by the National Institutes of Health.
Kynamro (mipomersen sodium) was the first antisense therapy to enter the dyslipidemia market. It is marketed by Kastle Therapeutics and is approved in the US for the treatment of homozygous familial hypercholesterolemia (HoFH).
Sotagliflozin (Lexicon/Sanofi) is an orally administered drug currently being investigated for the treatment of type 1 and type 2 diabetes. It is a dual inhibitor of the sodium-glucose cotransporter-1 (SGLT-1) and SGLT-2 transporters.
Tymlos (abaloparatide; Radius Health) is a synthetic peptide analog of human parathyroid hormone-related protein (PTHrP), which binds to the same receptor as parathyroid hormone (PTH). Endogenous PTHrP plays a central role in the regulation of endochondral bone development, with knockout mice not surviving past birth due to lack of proper bone development.
OncoVAX (Vaccinogen) is a personalized cancer vaccine that uses the patient’s own cancer cells to prevent tumor progression after surgery.
Toujeo (insulin glargine U300) is a long-acting basal insulin analog based on Sanofi’s hugely successful Lantus (insulin glargine) for use in the treatment of type 1 and type 2 diabetes. The new product is a formulation which is three times more concentrated than the original, with a reduced volume and surface area of the subcutaneous depot.
Vertex’s tezacaftor (formerly known as VX-661) is a CFTR corrector compound being investigated as an adjunct to Vertex’s other marketed and developmental CFTR-targeting products. The drug’s initial development is as part of a fixed-dose combination with the CFTR potentiator ivacaftor (Vertex), which was approved with the brand name Kalydeco in January 2012.
NovoEight (Novo Nordisk) is a B-domain deleted recombinant factor VIII (rfVIII) therapy developed for the treatment of adult and pediatric patients with hemophilia A.
Prolia (denosumab; Amgen/Daiichi Sankyo) is a fully human monoclonal antibody developed by Amgen for the treatment of osteoporosis.
Ultibro’s (indacaterol/glycopyrrolate bromide; Novartis/Pfizer) extensive clinical trial program for
chronic obstructive pulmonary disease (COPD) and its first-in-class status in Japan and select EU
markets boost its overall clinical and commercial attractiveness.
Taltz (ixekizumab; Eli Lilly/Torii Pharmaceutical) is a humanized, immunoglobulin G subclass 4 monoclonal antibody that neutralizes interleukin-17.
Solithromycin (Cempra Pharmaceuticals/Cubist Pharmaceuticals/Toyama Chemical) is a next-generation ketolide antibiotic. The drug, which is structurally related to the macrolide class of antibiotics, is the first fluoroketolide antibacterial in clinical development for bacterial infections, including CAP.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!